WEKO3
アイテム
{"_buckets": {"deposit": "0b0af6a1-e79d-45af-af31-18f905db091d"}, "_deposit": {"created_by": 3, "id": "149", "owners": [3], "pid": {"revision_id": 0, "type": "depid", "value": "149"}, "status": "published"}, "_oai": {"id": "oai:shiga-med.repo.nii.ac.jp:00000149", "sets": ["126"]}, "author_link": ["491", "494", "454", "492", "456", "302", "489", "490", "137", "165", "495"], "item_3_alternative_title_18": {"attribute_name": "その他の言語のタイトル", "attribute_value_mlt": [{"subitem_alternative_title": "Results of IMRT following neoadjuvant hormone therapy for clinical stage C prostate cancer"}]}, "item_3_alternative_title_19": {"attribute_name": "タイトル(ヨミ)", "attribute_value_mlt": [{"subitem_alternative_title": "Stage C ゼンリツセンガン ニ タイスル ナイブンピツ ホルモン リョウホウ ヘイヨウ キョウド ヘンチョウ ホウシャセン チリョウ IMRT ノ チュウキ チリョウ セイセキ"}]}, "item_3_biblio_info_6": {"attribute_name": "書誌情報", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2012-11-07", "bibliographicIssueDateType": "Issued"}, "bibliographicIssueNumber": "1", "bibliographicPageEnd": "12", "bibliographicPageStart": "6", "bibliographicVolumeNumber": "26", "bibliographic_titles": [{"bibliographic_title": "滋賀医科大学雑誌"}]}]}, "item_3_description_42": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"subitem_description": "Departmental Bulletin Paper", "subitem_description_type": "Other"}]}, "item_3_description_5": {"attribute_name": "内容記述", "attribute_value_mlt": [{"subitem_description": "We report the 5-year prostate-specific antigen (PSA) relapse-free survival outcome and incidence of toxicity forpatients with clinically Stage C prostate cancer treated with intensity-modulated radiation therapy (IMRT) in our institute. Atotal of 35 patients with Stage C prostate cancer were treated with IMRT between July 2003 and November 2007. All patientswere treated to a dose of 74Gy prescribed to the planning target volume and received neoadjuvant hormone therapy. Themedian age was 71 years (range: 50 to 80 years). 3 patients (8.6%) had Gleason scores <or=6, 14 patients (40.0%) hadGleason scores 7, 18 patients (51.4%) had Gleason scores \u003eor=8. The median pretreatment PSA level was 28.0 ng/mL (range:5.1 to 160.0 ng/mL). Patients were characterized as having high risk disease if their pretreatment PSA level was \u003e20ng/ml andGleason score \u003eor=8. PSA relapse-free survival rate were calculated and toxicity data were scored according to the CommonTerminology Criteria for Adverse Events Version 3.0. The median follow-up time was 58 months (range 7 to 84). 11 patients(31.4%) developed a PSA relapse, and the 5-year PSA relapse-free survival rate was 66.3%. The 5-year PSA relapse-freesurvival rates for high risk patients and others were 39.2% and 85.7%, respectively (p=0.0098). The likelihood of acute grade 2urinary and rectal toxicity was 14.2% and 11.4%. No grade 2 late complications have been observed. These results indicatedthat 74Gy IMRT is well tolerated and is associated with good PSA relapse-free survival outcomes in patients with Stage Cprostate cancer, especially non-high risk patient.", "subitem_description_type": "Other"}]}, "item_3_publisher_32": {"attribute_name": "出版者", "attribute_value_mlt": [{"subitem_publisher": "滋賀医科大学雑誌編集委員会"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "河野, 直明"}], "nameIdentifiers": [{"nameIdentifier": "456", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "邵, 啓全"}], "nameIdentifiers": [{"nameIdentifier": "165", "nameIdentifierScheme": "WEKO"}, {"nameIdentifier": "20283567", "nameIdentifierScheme": "e-Rad", "nameIdentifierURI": "https://kaken.nii.ac.jp/ja/search/?qm=20283567"}]}, {"creatorNames": [{"creatorName": "津川, 拓也"}], "nameIdentifiers": [{"nameIdentifier": "454", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "村田, 喜代史"}], "nameIdentifiers": [{"nameIdentifier": "137", "nameIdentifierScheme": "WEKO"}, {"nameIdentifier": "20127038", "nameIdentifierScheme": "e-Rad", "nameIdentifierURI": "https://kaken.nii.ac.jp/ja/search/?qm=20127038"}]}, {"creatorNames": [{"creatorName": "野間, 和夫"}], "nameIdentifiers": [{"nameIdentifier": "489", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "本多, 恵理子"}], "nameIdentifiers": [{"nameIdentifier": "490", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "橋本, 惠次"}], "nameIdentifiers": [{"nameIdentifier": "491", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "近藤, 康雄"}], "nameIdentifiers": [{"nameIdentifier": "492", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Ushida, Hiroshi"}], "nameIdentifiers": [{"nameIdentifier": "302", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "岡本, 圭生"}], "nameIdentifiers": [{"nameIdentifier": "494", "nameIdentifierScheme": "WEKO"}, {"nameIdentifier": "50303780", "nameIdentifierScheme": "e-Rad", "nameIdentifierURI": "https://kaken.nii.ac.jp/ja/search/?qm=50303780"}]}, {"creatorNames": [{"creatorName": "岡田, 裕作"}], "nameIdentifiers": [{"nameIdentifier": "495", "nameIdentifierScheme": "WEKO"}, {"nameIdentifier": "20127062", "nameIdentifierScheme": "e-Rad", "nameIdentifierURI": "https://kaken.nii.ac.jp/ja/search/?qm=20127062"}]}]}, "item_files": {"attribute_name": "ファイル情報", "attribute_type": "file", "attribute_value_mlt": [{"accessrole": "open_date", "date": [{"dateType": "Available", "dateValue": "2017-02-16"}], "displaytype": "detail", "download_preview_message": "", "file_order": 0, "filename": "jsums2601p006.pdf", "filesize": [{"value": "476.8 kB"}], "format": "application/pdf", "future_date_message": "", "is_thumbnail": false, "licensetype": "license_free", "mimetype": "application/pdf", "size": 476800.0, "url": {"label": "jsums2601p006.pdf", "url": "https://shiga-med.repo.nii.ac.jp/record/149/files/jsums2601p006.pdf"}, "version_id": "ff743b7a-561b-46cd-ac70-f1385ddbe821"}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "jpn"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "departmental bulletin paper", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": "Stage C 前立腺癌に対する内分泌ホルモン療法併用強度変調放射線治療(IMRT)の中期治療成績", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "Stage C 前立腺癌に対する内分泌ホルモン療法併用強度変調放射線治療(IMRT)の中期治療成績"}]}, "item_type_id": "3", "owner": "3", "path": ["126"], "permalink_uri": "http://hdl.handle.net/10422/1711", "pubdate": {"attribute_name": "公開日", "attribute_value": "2016-04-12"}, "publish_date": "2016-04-12", "publish_status": "0", "recid": "149", "relation": {}, "relation_version_is_last": true, "title": ["Stage C 前立腺癌に対する内分泌ホルモン療法併用強度変調放射線治療(IMRT)の中期治療成績"], "weko_shared_id": 3}
Stage C 前立腺癌に対する内分泌ホルモン療法併用強度変調放射線治療(IMRT)の中期治療成績
http://hdl.handle.net/10422/1711
http://hdl.handle.net/10422/1711e8255f7c-8af6-41d8-9bcd-521eef1b9bd2
名前 / ファイル | ライセンス | アクション |
---|---|---|
jsums2601p006.pdf (476.8 kB)
|
|
Item type | 紀要論文 / Departmental Bulletin Paper(1) | |||||
---|---|---|---|---|---|---|
公開日 | 2016-04-12 | |||||
タイトル | ||||||
タイトル | Stage C 前立腺癌に対する内分泌ホルモン療法併用強度変調放射線治療(IMRT)の中期治療成績 | |||||
言語 | ||||||
言語 | jpn | |||||
資源タイプ | ||||||
資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||
資源タイプ | departmental bulletin paper | |||||
その他のタイトル | ||||||
その他のタイトル | Results of IMRT following neoadjuvant hormone therapy for clinical stage C prostate cancer | |||||
タイトル(ヨミ) | ||||||
その他のタイトル | Stage C ゼンリツセンガン ニ タイスル ナイブンピツ ホルモン リョウホウ ヘイヨウ キョウド ヘンチョウ ホウシャセン チリョウ IMRT ノ チュウキ チリョウ セイセキ | |||||
著者 |
河野, 直明
× 河野, 直明× 邵, 啓全× 津川, 拓也× 村田, 喜代史× 野間, 和夫× 本多, 恵理子× 橋本, 惠次× 近藤, 康雄× Ushida, Hiroshi× 岡本, 圭生× 岡田, 裕作 |
|||||
内容記述 | ||||||
内容記述タイプ | Other | |||||
内容記述 | We report the 5-year prostate-specific antigen (PSA) relapse-free survival outcome and incidence of toxicity forpatients with clinically Stage C prostate cancer treated with intensity-modulated radiation therapy (IMRT) in our institute. Atotal of 35 patients with Stage C prostate cancer were treated with IMRT between July 2003 and November 2007. All patientswere treated to a dose of 74Gy prescribed to the planning target volume and received neoadjuvant hormone therapy. Themedian age was 71 years (range: 50 to 80 years). 3 patients (8.6%) had Gleason scores <or=6, 14 patients (40.0%) hadGleason scores 7, 18 patients (51.4%) had Gleason scores >or=8. The median pretreatment PSA level was 28.0 ng/mL (range:5.1 to 160.0 ng/mL). Patients were characterized as having high risk disease if their pretreatment PSA level was >20ng/ml andGleason score >or=8. PSA relapse-free survival rate were calculated and toxicity data were scored according to the CommonTerminology Criteria for Adverse Events Version 3.0. The median follow-up time was 58 months (range 7 to 84). 11 patients(31.4%) developed a PSA relapse, and the 5-year PSA relapse-free survival rate was 66.3%. The 5-year PSA relapse-freesurvival rates for high risk patients and others were 39.2% and 85.7%, respectively (p=0.0098). The likelihood of acute grade 2urinary and rectal toxicity was 14.2% and 11.4%. No grade 2 late complications have been observed. These results indicatedthat 74Gy IMRT is well tolerated and is associated with good PSA relapse-free survival outcomes in patients with Stage Cprostate cancer, especially non-high risk patient. | |||||
書誌情報 |
滋賀医科大学雑誌 巻 26, 号 1, p. 6-12, 発行日 2012-11-07 |
|||||
出版者 | ||||||
出版者 | 滋賀医科大学雑誌編集委員会 | |||||
資源タイプ | ||||||
内容記述タイプ | Other | |||||
内容記述 | Departmental Bulletin Paper |